Advertisement

Vaccines for Other Tumors

  • Michael A. Morse
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Although the brain is often considered an immunologically privileged site, animal models have demonstrated immunity against brain tumors following peripheral immunizations (1), direct intracerebral injections (2), or both (3). Potential targets of immunity against gliomas include the antigens ADP-ribosylation factor 4-like (ARF4L) (4), S ART 1 (5) and SART3 (6), UDP-Gal: 3G1cNAc ß1, 3-galactosyltransferase, polypeptide 3 (7), and the vIII mutation of human epidermal growth factor receptor. Although the autoimmune condition, experimental allergic encephalomyelitis, is a theoretical risk for immunizations with central nervous system (CNS) antigens, it is believed that the use of tumor-specific antigens will limit this risk.

Keywords

Human Epidermal Growth Factor Receptor Medullary Thyroid Carcinoma Experimental Allergic Encephalomyelitis Medullary Thyroid Cancer Parathyroid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Okada H, Villa L, Attanucci J, Erff M, Fellows WK, Lotze MT, et al. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther 2001; 8:1157–1166.PubMedCrossRefGoogle Scholar
  2. 2.
    DiMeco F, Rhines LD, Hanes J, Tyler BM, Brat D, Torchiana E, et al. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J Neurosurg 2000; 92:419–427.PubMedCrossRefGoogle Scholar
  3. 3.
    Iwadate Y, Yamaura A, Sato Y, Sakiyama S, Tagawa M. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors. Cancer Res 2001; 61:8769–8774.PubMedGoogle Scholar
  4. 4.
    Nonaka Y, Tsuda N, Shichijo S, Ito M, Maeda Y, Harada M, et al. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors. Tissue Antigens 2002; 60:319–327.PubMedCrossRefGoogle Scholar
  5. 5.
    Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Yutani S, Shigemori M, et al. Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 1999; 83:760–764.PubMedCrossRefGoogle Scholar
  6. 6.
    Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M, et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 2000; 23:511–518.PubMedCrossRefGoogle Scholar
  7. 7.
    Tsuda N, Nonaka Y, Shichijo S, Yamada A, Ito M, Maeda Y, et al. UDP-Gal: betaGlcNAc betal , 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour. Br J Cancer 2002; 87:1006–1012.PubMedCrossRefGoogle Scholar
  8. 8.
    Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842–847.PubMedGoogle Scholar
  9. 9.
    Graf MR, Prins RM, Hawkins WT, Merchant RE. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination. Cancer Immunol Immunother 2002; 51:179–189.PubMedCrossRefGoogle Scholar
  10. 10.
    Maio M, Coral S, Sigalotti L, Elisei R, Romei C, Rossi G, Cortini E, Colizzi F, Fenzi G, Altomonte M, Pinchera A, Vitale M. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 2003; 88:748–754.PubMedCrossRefGoogle Scholar
  11. 11.
    Lausson S, Fournes B, Borrel C, Milhaud G, Treilhou-Lahille F. Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma. Cancer Immunol Immunother 1996; 43:116–123.PubMedCrossRefGoogle Scholar
  12. 12.
    Schott M, Feldkamp J, Schattenberg D, Krueger T, Dotzenrath C, Seissler J, Scherbaum WA. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 2000; 142:300–306.PubMedCrossRefGoogle Scholar
  13. 13.
    Sarkar AK, Nuchtern JG. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 2000; 60:1908–1913.PubMedGoogle Scholar
  14. 14.
    Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101:1718–1726.PubMedCrossRefGoogle Scholar
  15. 15.
    Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61:8513–8519.PubMedGoogle Scholar
  16. 16.
    Cheung NK, Guo HF, Heller G, Cheung IY. Induction of Ab3 and Ab3’ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 2000; 6:2653–2660.PubMedGoogle Scholar
  17. 17.
    Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 2002; 62:5049–5057.PubMedGoogle Scholar
  18. 18.
    Chang AE, Li Q, Jiang G, Teknos TN, Chepeha DB, Bradford CR. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head Neck 2003; 25:198–209.PubMedCrossRefGoogle Scholar
  19. 19.
    To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000; 126:1225–1231.PubMedGoogle Scholar
  20. 20.
    Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62:6952–6958.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Michael A. Morse

There are no affiliations available

Personalised recommendations